Navigation Links
UAlberta prostate cancer researcher and team developing 'homing beacon drugs' to target cancer cells
Date:11/20/2012

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research with the Faculty of Medicine & Dentistry, published his findings in the peer-reviewed journal, Nano Letters. He is also an associate professor in the Department of Oncology, a Fellow with the National Institute for Nanotechnology at the U of A and director of the Translational Prostate Cancer Research Group.

Lewis noted chemotherapy goes through the body and kills any cells that are dividing, even healthy ones which is why cancer patients have immune system problems, hair loss, nausea and skin problems.

"We are developing smart drugs that determine which are the cancer cells and which aren't, then selectively kill only the cancer cells. The drugs look for a protein that is only found in cancer cells, not normal cells. This system acts like a homing beacon for tumours."

These drugs, tested to date in only animal lab models, could be used within a week of cancer diagnoses, predicts Lewis. The drugs would target cancerous cells throughout the body attacking sneaky cancer cells that have already escaped and grown outside the site of the main tumour.

Lewis wasn't sure when these homing beacon drugs could be available for physicians to use with patients, but hopes his works paves the way for patient-centered therapies.

"If we can use 'smart' drugs that home in on tumours, we can dramatically decrease side effects for patients, lower the chance of recurrence, and hopefully increase the cancer survival rate."

Meanwhile, Lewis and his research team are continuing their work on trying to figure out what causes cancer cells to escape and spread from the main tumour site because the cells that move are different than the ones in the main tumour. They have pinpointed numerous genes that set these 'moving' cancer cells apart from the ones that stay put. Based on this research, they have come up with a drug that uses a 'tumour glue' to prevent these moving cancer cells from breaking apart from the main tumour, which prevents the spread of the cancer. Using knowledge gained from the 'tumour glue' drug, Lewis and his team are working to develop new blood tests to predict whether prostate and other cancers will spread.


'/>"/>

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related medicine news :

1. Prostate Cancer Websites Often Hard to Understand: Study
2. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
3. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
4. Active surveillance can reduce suffering among men with prostate cancer
5. Prostate cancer prognosis hope
6. Proton therapy treatment preserves quality of life for men with prostate cancer
7. For many prostate cancer patients, Web sites are too difficult to read
8. Viagra Can Help Prostate Cancer Patients Maintain Sex Lives: Study
9. Drop in testosterone tied to prostate cancer recurrence
10. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
11. First web-based prostate cancer database launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume ... Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... can pick and choose from hand-crafted trend-setting designs with smooth animations that will ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits ... effects allegedly associated with use of the atypical antipsychotic ... Philadelphia Court of Common Pleas, where the ... tort program. According to a notice posted on the ... convene a meeting on March 9, 2017 at 11:00 ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology: